165 Contribution of TOX1 and STAT3 pathways to the development of cutaneous T-cell lymphoma (CTCL)

Abstract

Thymocyte selection associated high mobility group box 1 (Tox1), a transcription factor that is essential to establish the CD4+ lineage, is overexpressed in malignant cells from patients with CTCL. Knockdown of Tox1 leads to decreased malignant cell viability, while treatment with HDAC inhibitors results in normalization of Tox1expression. Another gene which is consistently overexpressed in patient samples is signal transducers and activators of transcription3 (Stat3), a transcription factor essential for the differentiation of Th17 and follicular helper T cells. Treating CTCL cell lines with a STAT3 inhibitor results in decreased cell number and increased apoptosis, highlighting the importance of this pathway for malignant cell survival. Importantly, the Koralov lab has developed a mouse model which constitutively expresses a hyperactive STAT3 allele, STAT3C, that recapitulates several key features of MF. To examine the contribution of TOX1overexpression to CTCL pathogenesis, we have introduced Tox1 cDNA downstream of a floxed stop cassette into the ubiquitously expressed Rosa26 locus of C57Bl/6J embryonic stem (ES) cells. We have screened the ES clones to validate the presence of the correctly targeted allele, and we have treated ES clones with TAT-Cre to delete the floxed stop cassette and drive subsequent expression of Tox1 cDNA. We have now generated R26Tox1stopflmice using tetraploid complementation to generate 100% ES cell derived animals. These animals will be crossed to CD4Cre and CD4Cre STAT3Cstopflstrains, thus enabling us to study the contribution of Tox1 overexpression to T cell lymphomagenesis and allowing us to examine synergy between Tox1 overexpression and hyperactive STAT3 signaling in CTCL pathogenesis. We hope that these mice will pave the way to a better understanding of this enigmatic malignancy and allow us to develop a relevant small animal model of this disease.